Dihydroberberine (CAS: 483-15-8) is a reduced derivative of berberine. Compared to berberine, it exhibits 3-5 times higher bioavailability (oral absorption rate >50%) with stronger AMPK activation and more pronounced glucose/lipid-modulating effects. Preclinical studies demonstrate its ability to reduce fasting blood glucose by 40% (at 50mg/kg dose) in diabetic models while improving insulin sensitivity (35% decrease in HOMA-IR index). As a novel metabolic modulator, its liver-targeting properties and gut microbiota regulation (increasing Akkermansia abundance) have attracted significant attention, currently completing Phase II clinical trials for non-alcoholic fatty liver disease treatment.